If this message is not displaying properly, click here.     Giving your patients access to free IS RQ-PCR testing has never been easier     Dear Health Care Provider, Try IS RQ-PCR for free— Sign up online today     It’s never been easier to get free IS RQ-PCR testing for your patients with Ph+ CML. Introducing GetISRQPCRNow.com, the online home for the free IS RQ-PCR testing program from Novartis. The Get IS RQ-PCR Now program provides free IS RQ-PCR testing through December 31, 2014.* Both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and ELN recommend testing with RQ-PCR standardized to the IS for patients with Ph+ CML.1,2 • This easy-to-use blood test is the most sensitive test available, providing the most precise measurement of BCR-ABL—the cause of Ph+ CML1 • Only IS-standardized results provide the accuracy, clarity, and comparability that is essential to measuring the true response of your patients with Ph+ CML3 NCCN Guidelines® recommend monitoring with IS RQ-PCR every 3 months and achieving the following milestones at the months indicated1 Month Recommended response Sign of failure 3 <10% IS BCR-ABL transcripts or PCyR >10% IS BCR-ABL mRNA or no PCyR 12 CCyR <CCyR 18 CCyR <CCyR 18+ No relapse Relapse (hematologic, cytogenetic, or 1-log increase in BCR-ABL mRNA and loss of MMR) NCCN Guidelines advise considering a change of therapy if treatment milestones are not achieved.1 Enrolling is easy— Sign up online today *Up to 22 tests per patient. IS, international scale; RQ-PCR, real-time quantitative polymerase chain reaction; Ph+ CML, Philadelphia chromosome–positive chronic myeloid leukemia; NCCN®, National Comprehensive Cancer Network®; ELN, European LeukemiaNet; OS, overall survival; PFS, progression-free survival; PCyR, partial cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response. References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia Version 4.2013. © 2013 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed July 22, 2013. To view the most recent and complete version of the guidelines, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [published online June 26, 2013]. Blood. doi:10.1182/blood-2013-05-501569. 3. Jabbour EJ, Quintàs-Cardama A. Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response. Leuk Lymphoma. 2012;53(8):1452-1450. If you prefer not to receive any future promotional e-mail communications from Novartis Pharmaceuticals Corporation, please click here. If you have any questions concerning e-mail or marketing communications from Novartis Pharmaceuticals Corporation, please call 1-888-NOW-NOVA (1-888-669-6682), Monday-Friday, 8:30 am-5:00 pm ET. For more information, please visit the Novartis Privacy Policy.       Novartis Pharmaceuticals Corporation     One Health Plaza     East Hanover, New Jersey 07936-1080 © 2013 Novartis 9/13 CDE-1070504     Unsubscribe  |  Privacy Statement